PatientsVille.com Logo

ANGIOEDEMA and Diclofenac

PatientsVille

ANGIOEDEMA Symptoms and Causes

Hives are red and sometimes itchy bumps on your skin. An allergic reaction to a drug or food usually causes them. Allergic reactions cause your body to release chemicals that can make your skin swell up in hives. People who have other allergies are more likely to get hives than other people. Other causes include infections and stress.

Hives are very common. They usually go away on their own, but if you have a serious case, you might need medicine or a shot. In rare cases, hives can cause a dangerous swelling in your airways, making it hard to breathe - which is a medical emergency.

Check out the latest treatments for ANGIOEDEMA

ANGIOEDEMA treatment research studies

Diclofenac clinical trials, surveys and public health registries


Find Drug Side Effect reports



Diclofenac Side Effects

Renal Failure Acute (154)
Abdominal Pain (139)
Diarrhoea (136)
Vomiting (128)
Dyspnoea (103)
Haemoglobin Decreased (103)
Gastrointestinal Haemorrhage (102)
Nausea (88)
Blood Creatinine Increased (88)
Anaemia (86)
Malaise (83)
Dehydration (82)
Pruritus (79)
Abdominal Pain Upper (77)
Blood Urea Increased (76)
Dizziness (72)
Gastric Ulcer (68)
Gastrointestinal Disorder (68)
Haematemesis (64)
Anaphylactic Reaction (62)
Pyrexia (61)
Erythema (60)
Fatigue (60)
Pain (60)
Hypotension (57)
Melaena (56)
Embolia Cutis Medicamentosa (54)
Chest Pain (54)
Arthralgia (53)
Rash (53)
Oedema Peripheral (51)
Asthenia (50)
Loss Of Consciousness (49)
Alanine Aminotransferase Increased (49)
Fall (48)
Headache (47)
Blood Alkaline Phosphatase Increased (47)
Metabolic Acidosis (46)
Gastritis (46)
Renal Failure (45)
Cardiac Arrest (44)
Confusional State (43)
Back Pain (43)
C-reactive Protein Increased (43)
Convulsion (43)
Urticaria (43)
Blood Pressure Decreased (41)
Weight Decreased (41)
Peritonitis (41)
Aspartate Aminotransferase Increased (40)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

ANGIOEDEMA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
Condition: Hereditary Angioedema Types I and II
Interventions: Biological: Low-volume C1-esterase inhibitor;   Biological: Higher-volume C1-esterase inhibitor;   Biological: Low-volume placebo;   Biological: Higher-volume placebo
Outcome Measures: The time-normalized number of hereditary Angioedema attacks;   Proportion of subjects with a 50% reduction in the number of hereditary Angioedema attacks;   Number of uses of rescue medication;   Proportion of subjects with any adverse events
2 Recruiting Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
Condition: Hereditary Angioedema
Intervention: Biological: CINRYZE
Outcome Measures: Number of Angioedema attacks in each treatment period;   Number of subjects with adverse events by dose group;   Change from baseline in C1 inhibitor (C1 INH) and C4 concentrations during each treatment period;   Number of subjects with C1 INH antibodies
3 Not yet recruiting Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
Condition: Hereditary Angioedema Types I and II
Intervention: Drug: Ecallantide subcutaneous dosing
Outcome Measures: Measurement of time to symptomatic improvement from acute attacks of hereditary Angioedema;   Number of Partcipants with Adverse Events
4 Recruiting Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
Condition: ACE Inhibitor-associated Angioedema
Interventions: Drug: icatibant;   Other: Placebo
Outcome Measures: Time to resolution of Angioedema;   Length of hospital stay;   Admission to intensive care unit;   Requirement for intubation;   Duration of intubation;   Use of steroids;   Use of histamine receptor type 1 (H1) and type 2 (H2) blockers;   Use of epinephrine;   Blood pressure levels
5 Unknown  Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Condition: Angioedema
Intervention: Drug: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Outcome Measures: Objective criteria that allow for discharge directly from the ED at or before 4 hours:(stable vital signs, no evidence of stridor, dysphagia or drooling, edema has regressed to or did not progress beyond Class I.;   Time to meet objective discharge criteria, Physician assessment of Angioedema improvement measured using the Symptom Complex Response Assessment at 2 hours post-treatment and 4 hours post-treatment.
6 Recruiting C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
Condition: Hereditary Angioedema
Intervention: Drug: rhC1INH or pdC1INH
Outcome Measures: The primary objective is to observe the adverse event profile and insufficient efficacy, following single and repeated treatment with Ruconest or pdC1INHof acute Angioedema attacks;   To assess the immunological profile of Ruconest (for suspected hypersensitivity or suspected neutralizing antibodies)
7 Recruiting Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Angioedema
Condition: Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Interventions: Drug: Icatibant;   Drug: Placebo
Outcome Measures: Time to Meeting Discharge Criteria (TMDC).;   Safety and tolerability of Icatibant.;   Time to Onset of Symptom Relief (TOSR).;   Occurrence of airway intervention due to ACE-I-induced Angioedema.;   Admission to the hospital or intensive care unit (ICU).;   Angioedema attack following study drug administration.;   Time to meeting discharge criteria (TMDC).
8 Recruiting A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Condition: Hereditary Angioedema
Intervention: Drug: icatibant
Outcome Measures: Pharmacokinetic (PK) Profile after a single SC injection (in prepubertal children with an acute attack of HAE and pubertal/postpubertal children with or without an acute attack of HAE);   Safety of a single SC dose of icatibant;   Time to onset of relief of symptoms and time to minimal symptoms, as measured by investigator- and subject-reported outcomes for subjects who have experienced HAE attack only;   Proportion of subjects with worsened intensity of clinical HAE symptoms between 2 and 4 hours after treatment with icatibant for subjects who have experienced HAE attack only;   Incidence of rescue medication use for subjects who have experienced HAE attack only
9 Unknown  The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema
Conditions: Urticaria;   Angioedema
Intervention: Behavioral: Dietary Therapy
Outcome Measures: The frequency and severity of CIU and/or Angioedema (as determined via a five point rating scale);   The relative use of antihistamines (ie how many, how often)
10 Recruiting Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Condition: Hereditary Angioedema
Intervention: Drug: rhC1INH
Outcome Measures: The primary objective is the assessment of safety and tolerability (adverse events, physical examination, vital signs, immunological and routine laboratory analyses et cetera);   Immunogenicity by assessing antibodies against recombinant human C1INH (IgG and IgM) anti-rhC1INH);   Immunogenicity by assessing antibodies against host related impurities (anti-HRI);   Immunogenicity by assessing IgE antibodies against rabbit epithelium;   Beginning of relief;   Minimal symptoms;   Complete resolution;   Pharmacokinetic parameters for first attack;   Pharmacodynamic parameters for first attack
11 Recruiting A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Condition: Hereditary Angioedema
Intervention:
Outcome Measures: Incidence of adverse drug reactions;   Incidence of thrombotic/thromboembolic events;   Occurrence of pregnancy
12 Recruiting Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema
Condition: Acute ACE-induced Angioedema
Interventions: Drug: Berinert;   Drug: Clemastin;   Drug: Cortisone acetate;   Drug: NaCl
Outcome Measure: time of resolution
13 Recruiting Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema
Condition: Hereditary Angioedema
Intervention: Drug: Icatibant
Outcome Measure: Time to complete or near complete resolution from onset of symptoms
14 Recruiting A Call Center During HAE Attacks (SOS HAE)
Condition: Hereditary Angioedema
Intervention: Other: phone to the call center
Outcome Measures: Percentage of patients hospitalized per year for an observation period of two years at 2 years;   Number of hospitalizations per year in intensive care unit [Time Frame : 2 years];   Number of emergency departments visits per year [Time Frame : 2 years];   Number of hospitalizations [Time Frame : 2 years];   Number of intubations per year [Time Frame : 2 years];   Number of interventions of Emergency Medical System [Time Frame : 2 years];   Number of stop disease and duration [Time Frame : 2 years];   Mortality [Time Frame : 2 years];   Cost of the hospitalization
15 Recruiting Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Condition: Hereditary Angioedema
Interventions: Drug: DX-2930;   Drug: Placebo
Outcome Measures: proportion of patients with non-serious and serious adverse events;   DX-2930 plasma level
16 Recruiting Pharmacogenetics of Ace Inhibitor-Associated Angioedema
Conditions: Hypertension;   Diabetes Type 2
Interventions: Drug: Sitagliptin;   Drug: Substance P,;   Drug: bradykinin;   Drug: enalaprilat;   Drug: Glucagon-like peptide 1;   Drug: brain natriuretic peptide
Outcome Measures: The effect of enalaprilat, sitagliptin, or the combination on the vasodilator response (forearm blood flow) to substance P and bradykinin (Group 1) or glucagon like peptide-1 and brain naturetic peptide (Group 2).;   Assess peptide concentrations, nitric oxide metabolites, tissue type plasminogen activator, glucose, and catecholamines
17 Recruiting Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists
Conditions: Hospitalized Cases of Angioneurotic Oedema;   Pneumonia;   Gastroenteritis;   Failure to Thrive;   Seizures;   Acute Interstitial Nephritis and Thrombocytopenia
Intervention:
Outcome Measures: Drug utilization: Description of patient characteristics and drug usage;   Follow-up of safety outcomes: First occurrence of hospitalized angioneurotic oedema, pneumonia, gastroenteritis, failure to thrive, convulsions/seizures, acute interstitial nephritis and thrombocytopenia
18 Recruiting Screening Protocol for Genetic Diseases of Mast Cell Homeostasis and Activation
Conditions: Piebaldism;   Idiopathic Anaphylaxis;   Allergy;   Chronic Urticara;   Angioedema
Intervention:
Outcome Measure: Designed to screen subjects with suspected or identified genetic diseases of mast cell homeostasis and activation. Blood specimens will be obtained for research studies related to understanding the genetic and biochemical bases of these diseases...
19 Recruiting Firazyr® Patient Registry Protocol (Icatibant Outcome Survey - IOS)
Condition: Angioedemas, Hereditary
Intervention:
Outcome Measure: To monitor the safety of Firazyr® during long-term treatment
20 Recruiting A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Conditions: Anaphylaxis;   Hypotension;   Bronchospasm;   Angioedema
Interventions: Drug: Epinephrine;   Procedure: Bone Marrow Apsiration;   Drug: Omalizumab (Xolair)
Outcome Measures: The primary objective of this study is to determine if treatment with omalizumab over 6 months will produce a reduction in the number and timing of anaphylactic events in subjects with a history of frequent idiopathic anaphylaxis.;   Assess the pharmacodynamics of omalizumab in subjects with anaphylaxis. Examine the effects of omalizumab in the immunopathogenesis of anaphylaxis. Identify subjects with the D816V mutation.